JP2019515027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515027A5 JP2019515027A5 JP2019505138A JP2019505138A JP2019515027A5 JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5 JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5
- Authority
- JP
- Japan
- Prior art keywords
- binding fragment
- antigen
- hvegf
- hvegf antigen
- glycosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022108815A JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US62/323,285 | 2016-04-15 | ||
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US62/442,802 | 2017-01-05 | ||
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US62/450,438 | 2017-01-25 | ||
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| US62/460,428 | 2017-02-17 | ||
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108815A Division JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515027A JP2019515027A (ja) | 2019-06-06 |
| JP2019515027A5 true JP2019515027A5 (enExample) | 2020-05-28 |
Family
ID=60041925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (enExample) |
| EP (1) | EP3442577A4 (enExample) |
| JP (3) | JP2019515027A (enExample) |
| KR (2) | KR20190003556A (enExample) |
| AU (2) | AU2017250797A1 (enExample) |
| CA (1) | CA3019665A1 (enExample) |
| IL (1) | IL262277A (enExample) |
| SG (2) | SG10202008378UA (enExample) |
| WO (1) | WO2017181021A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| IL322403A (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| JP7685833B2 (ja) * | 2017-09-27 | 2025-05-30 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| US12558434B2 (en) * | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| US12275948B2 (en) * | 2018-06-28 | 2025-04-15 | The University Of North Carolina At Chapel Hill | Optimized CLN5 genes and expression cassettes and their use |
| AU2019377115A1 (en) * | 2018-11-07 | 2021-05-20 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| EP3946467A1 (en) | 2019-04-03 | 2022-02-09 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| WO2020219868A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| KR20220049568A (ko) * | 2019-08-22 | 2022-04-21 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 엔젤만 증후군의 치료를 위한 ube3a |
| CN114502197A (zh) * | 2019-08-26 | 2022-05-13 | 再生生物股份有限公司 | 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变 |
| US20240108669A1 (en) | 2019-10-07 | 2024-04-04 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| US20240024508A1 (en) | 2020-10-07 | 2024-01-25 | Regenxbio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| KR20230083287A (ko) | 2020-10-07 | 2023-06-09 | 리젠엑스바이오 인크. | Cln2 질환의 안구 징후에 대한 유전자 요법 |
| IL301947A (en) | 2020-10-07 | 2023-06-01 | Regenxbio Inc | Formulations for suprachoroidal administration such as gel formulations |
| WO2022076591A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| TW202233841A (zh) * | 2020-10-28 | 2022-09-01 | 美商銳進科斯生物股份有限公司 | 用於眼適應症之載體化抗ＴＮＦ－α抗體 |
| AU2021391433A1 (en) | 2020-12-01 | 2023-06-22 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| AU2021399147A1 (en) * | 2020-12-18 | 2023-07-27 | Ac Immune Sa | Antibody delivery |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| KR20230162942A (ko) * | 2021-03-31 | 2023-11-29 | 우시 바이올로직스 아일랜드 리미티드 | 이중특이성 항 pd-l1/vegf 항체 및 이의 용도 |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| CA3247507A1 (en) | 2022-04-06 | 2023-10-12 | Regenxbio Inc. | PHARMACEUTICAL COMPOSITION COMPRISING A RECOMMENDED ADENO-ASSOCIATED VIRUS (AAV) VECTOR WITH AN EXPRESSION CASSETTE ENCODED BY A TRANSGENE FOR SUPRACHOROID ADMINISTRATION |
| US20260034250A1 (en) | 2022-09-30 | 2026-02-05 | Regenxbio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1224309A2 (en) * | 1999-10-21 | 2002-07-24 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| CN1461342A (zh) * | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| TWI510248B (zh) * | 2009-06-17 | 2015-12-01 | Abbvie Biotherapeutics Inc | 抗－ｖｅｇｆ抗體及其用途 |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI702955B (zh) * | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ） |
| DK3142750T3 (da) * | 2014-05-13 | 2020-09-14 | Univ Pennsylvania | Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf |
-
2017
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Pending
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515027A5 (enExample) | ||
| JP7523491B2 (ja) | Ｐｄ－１、ｔｉｍ－３、およびｌａｇ－３を標的とする併用治療 | |
| JP2016504416A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2016188209A5 (enExample) | ||
| RU2015121755A (ru) | Антагонисты ил-6 и их применение | |
| RU2018125515A (ru) | Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2018506277A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| IL276383B2 (en) | Treatment of ophthalmologic diseases | |
| JP2018517431A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2017501711A5 (enExample) | ||
| HRP20150281T1 (hr) | Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa | |
| JP2017535257A5 (enExample) | ||
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| JP2016094424A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| JP2019530427A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2019532617A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2017534645A5 (enExample) |